<p>Aytu BioPharma 最近的財報電話會議充滿了樂觀和戰略重點。公司對即將推出的 ExuA（治療重度抑鬱症的新型療法）表示了極大的熱情，並慶祝其連續第三年實現正向調整後 EBITDA。然而，會議也承認了一些挑戰，例如毛利率下降和 ADHD 產品組合中潛在的競爭，這可能會在未來構成障礙。</p>
<h2>ExuA 推出計劃</h2>
<p>Aytu BioPharma 正在為 ExuA 的推出做準備，這是一種突破性的重度抑鬱症（MDD）治療藥物。這種首創藥物預計將顯著改變公司的市場地位。ExuA 作為 5-HT1A 受體激動劑的獨特機制旨在滿足 MDD 市場中未被滿足的需求，通過減少與現有治療相關的常見副作用，如性功能障礙和體重增加。</p>
<h2>正向調整後 EBITDA</h2>
<p>公司報告了連續第三年的正向調整後 EBITDA，達到 920 萬美元（2025 財年）。這一成就突顯了 Aytu BioPharma 的財務穩定性和有效的成本管理策略，增強了投資者對公司財務健康的信心。</p>
<h2>兒科產品組合增長</h2>
<p>Aytu BioPharma 的兒科產品組合表現出增長，淨收入從 730 萬美元增加到 880 萬美元。這一增長反映了公司復甦增長計劃的成功，突顯了其擴展和利用兒科產品的能力。</p>
<h2>成功融資</h2>
<p>公司完成了一次成功的市場公開募股，籌集了 1660 萬美元的總額和近 1500 萬美元的淨額。這輪融資由專注於醫療保健的機構投資者主導，為 Aytu BioPharma 提供了支持其戰略舉措和未來增長所需的資本。</p>
<h2>毛利率下降</h2>
<p>Aytu BioPharma 面臨毛利率下降，從 75% 降至 69%。這一下降歸因於 ADHD 庫存銷售成本的增加，主要是由於關閉製造設施帶來的間接成本。公司專注於通過改善產品包裝和成本結構來優化毛利率。</p>
<h2>ADHD 產品組合穩定性擔憂</h2>
<p>ADHD 產品組合的淨收入保持相對平穩，為 5760 萬美元，較 5780 萬美元略有下降，引發了對潛在仿製藥競爭的擔憂。公司意識到這些挑戰，可能會專注於維持其市場地位的策略。</p>
<h2>減值費用影響</h2>
<p>在兒科產品組合上記錄了 830 萬美元的減值費用。這是由於戰略重心轉向 ExuA 和 ADHD 產品組合，表明資源的重新配置以利用更有前景的機會。</p>
<h2>前瞻性指導</h2>
<p>Aytu BioPharma 提供了 2025 財年的前瞻性指導，報告淨收入為 6640 萬美元，並強調 ExuA 即將推出的影響。公司計劃利用其 Aytu RxConnect 平台實現高效的市場滲透，並準備在 2025 年底之前推出 ExuA。此外，Aytu 計劃在 2026 財年投資約 1000 萬美元用於 ExuA 的推出，並預計在隨後的幾個季度顯著提升商業運營。</p>
<p>總之，Aytu BioPharma 的財報電話會議傳達了積極的前景，受到 ExuA 預期推出和持續財務表現的推動。儘管承認了毛利率下降和 ADHD 市場潛在競爭等挑戰，但公司的戰略舉措和財務成就為未來的增長提供了堅實的基礎。</p>

AYTU

<p>Aytu BioPharma 的財報電話會議強調了對 ExuA 這一新型重度抑鬱症治療藥物上市的樂觀情緒，並報告了 2025 財年的調整後息税折舊攤銷前利潤（EBITDA）為 920 萬美元。公司面臨挑戰，包括毛利率從 75% 下降至 69%，以及由於潛在競爭對其注意力缺陷多動障礙（ADHD）產品組合的擔憂。Aytu 的兒科產品組合有所增長，公司通過公開發行籌集了 1660 萬美元。展望未來，Aytu 預計 2025 財年的淨收入為 6640 萬美元，並計劃在 ExuA 的上市上投資 1000 萬美元</p>

<p>Aytu BioPharma’s recent earnings call was marked by a sense of optimism and strategic focus. The company expressed significant enthusiasm about the upcoming launch of ExuA, a novel treatment for major depressive disorder, and celebrated its third consecutive year of positive adjusted EBITDA. However, the call also acknowledged challenges such as a decline in gross margin and potential competition in the ADHD portfolio, which could pose hurdles moving forward.</p>
<div class="lb-trans"><p>Aytu BioPharma 最近的財報電話會議充滿了樂觀和戰略重點。公司對即將推出的 ExuA（治療重度抑鬱症的新型療法）表示了極大的熱情，並慶祝其連續第三年實現正向調整後 EBITDA。然而，會議也承認了一些挑戰，例如毛利率下降和 ADHD 產品組合中潛在的競爭，這可能會在未來構成障礙。</p>
</div><h2>ExuA Launch Plans</h2>
<div class="lb-trans"><h2>ExuA 推出計劃</h2>
</div><p>Aytu BioPharma is gearing up for the launch of ExuA, a groundbreaking treatment for major depressive disorder (MDD). This first-in-class medication is expected to significantly transform the company’s market presence. ExuA’s unique mechanism as a 5-HT1A receptor agonist aims to address unmet needs in the MDD market by reducing common side effects associated with existing treatments, such as sexual dysfunction and weight gain.</p>
<div class="lb-trans"><p>Aytu BioPharma 正在為 ExuA 的推出做準備，這是一種突破性的重度抑鬱症（MDD）治療藥物。這種首創藥物預計將顯著改變公司的市場地位。ExuA 作為 5-HT1A 受體激動劑的獨特機制旨在滿足 MDD 市場中未被滿足的需求，通過減少與現有治療相關的常見副作用，如性功能障礙和體重增加。</p>
</div><h2>Positive Adjusted EBITDA</h2>
<div class="lb-trans"><h2>正向調整後 EBITDA</h2>
</div><p>The company reported a positive adjusted EBITDA for the third consecutive year, reaching $9.2 million for fiscal 2025. This achievement underscores Aytu BioPharma’s financial stability and effective cost management strategies, reinforcing investor confidence in the company’s financial health.</p>
<div class="lb-trans"><p>公司報告了連續第三年的正向調整後 EBITDA，達到 920 萬美元（2025 財年）。這一成就突顯了 Aytu BioPharma 的財務穩定性和有效的成本管理策略，增強了投資者對公司財務健康的信心。</p>
</div><h2>Pediatric Portfolio Growth</h2>
<div class="lb-trans"><h2>兒科產品組合增長</h2>
</div><p>Aytu BioPharma’s pediatric portfolio demonstrated growth, with net revenue increasing from $7.3 million to $8.8 million. This growth reflects the success of the company’s return to growth plan, highlighting its ability to expand and capitalize on its pediatric offerings.</p>
<div class="lb-trans"><p>Aytu BioPharma 的兒科產品組合表現出增長，淨收入從 730 萬美元增加到 880 萬美元。這一增長反映了公司復甦增長計劃的成功，突顯了其擴展和利用兒科產品的能力。</p>
</div><h2>Successful Financing</h2>
<div class="lb-trans"><h2>成功融資</h2>
</div><p>The company completed a successful at-the-market public offering, raising $16.6 million gross and just under $15 million net. This financing round was led by healthcare-focused institutional investors, providing Aytu BioPharma with the capital needed to support its strategic initiatives and future growth.</p>
<div class="lb-trans"><p>公司完成了一次成功的市場公開募股，籌集了 1660 萬美元的總額和近 1500 萬美元的淨額。這輪融資由專注於醫療保健的機構投資者主導，為 Aytu BioPharma 提供了支持其戰略舉措和未來增長所需的資本。</p>
</div><h2>Decline in Gross Margin</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>Aytu BioPharma faced a decline in gross margin, which decreased from 75% to 69%. This drop was attributed to increased cost of sales in the ADHD inventory, primarily due to overhead costs from a closed manufacturing facility. The company is focused on optimizing gross margins through improved product packaging and cost structures.</p>
<div class="lb-trans"><p>Aytu BioPharma 面臨毛利率下降，從 75% 降至 69%。這一下降歸因於 ADHD 庫存銷售成本的增加，主要是由於關閉製造設施帶來的間接成本。公司專注於通過改善產品包裝和成本結構來優化毛利率。</p>
</div><h2>ADHD Portfolio Stability Concerns</h2>
<div class="lb-trans"><h2>ADHD 產品組合穩定性擔憂</h2>
</div><p>The ADHD portfolio’s net revenue remained relatively flat at $57.6 million compared to $57.8 million, raising concerns about potential generic competition. The company is aware of these challenges and is likely to focus on strategies to maintain its market position.</p>
<div class="lb-trans"><p>ADHD 產品組合的淨收入保持相對平穩，為 5760 萬美元，較 5780 萬美元略有下降，引發了對潛在仿製藥競爭的擔憂。公司意識到這些挑戰，可能會專注於維持其市場地位的策略。</p>
</div><h2>Impairment Expense Impact</h2>
<div class="lb-trans"><h2>減值費用影響</h2>
</div><p>An $8.3 million impairment expense was recorded on the pediatric portfolio. This was due to a strategic shift in focus towards ExuA and the ADHD portfolio, indicating a realignment of resources to capitalize on more promising opportunities.</p>
<div class="lb-trans"><p>在兒科產品組合上記錄了 830 萬美元的減值費用。這是由於戰略重心轉向 ExuA 和 ADHD 產品組合，表明資源的重新配置以利用更有前景的機會。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指導</h2>
</div><p>Aytu BioPharma provided forward-looking guidance for fiscal 2025, reporting net revenue of $66.4 million and emphasizing the impact of ExuA’s upcoming launch. The company plans to leverage its Aytu RxConnect platform for efficient market penetration and is preparing for ExuA’s commercial launch by the end of 2025. Additionally, Aytu plans to invest approximately $10 million in launching ExuA in fiscal 2026, with expectations to ramp up commercial operations significantly in the subsequent quarters.</p>
<div class="lb-trans"><p>Aytu BioPharma 提供了 2025 財年的前瞻性指導，報告淨收入為 6640 萬美元，並強調 ExuA 即將推出的影響。公司計劃利用其 Aytu RxConnect 平台實現高效的市場滲透，並準備在 2025 年底之前推出 ExuA。此外，Aytu 計劃在 2026 財年投資約 1000 萬美元用於 ExuA 的推出，並預計在隨後的幾個季度顯著提升商業運營。</p>
</div><p>In summary, Aytu BioPharma’s earnings call conveyed a positive outlook, driven by the anticipated launch of ExuA and sustained financial performance. While challenges such as declining gross margins and potential competition in the ADHD market were acknowledged, the company’s strategic initiatives and financial achievements provide a solid foundation for future growth.</p>
<div class="lb-trans"><p>總之，Aytu BioPharma 的財報電話會議傳達了積極的前景，受到 ExuA 預期推出和持續財務表現的推動。儘管承認了毛利率下降和 ADHD 市場潛在競爭等挑戰，但公司的戰略舉措和財務成就為未來的增長提供了堅實的基礎。</p>
</div>

Aytu BioPharma 樂觀的財報電話會議重點介紹了 ExuA 的推出